PROTEUS
What it tests: Perioperative apalutamide plus ADT with radical prostatectomy and pelvic lymph node dissection versus placebo plus ADT in high-risk localized or locally advanced prostate cancer.

Listen to Oncology Here & Now
ESMO 2026On demandMadrid, October 23–27See the ESMO 2026 highlightsSubscribe to the newsletterWhat it tests: Perioperative apalutamide plus ADT with radical prostatectomy and pelvic lymph node dissection versus placebo plus ADT in high-risk localized or locally advanced prostate cancer.
The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.